

AUTHOR INDEX FOR VOLUME 30

A

- Abrahamsson, T., *see* Nerme, V., 1
 Adamik, R., *see* Tsai, S.-C., 274
 Andersson, T., Dahlgren, C., Pozzan, T., Stendahl, O., and Lew, D. P. Characterization of fMet-Leu-Phe receptor-mediated Ca^{2+} influx across the plasma membrane of human neutrophils, 437
 Andrews, P. A., Murphy, M. P., and Howell, S. B. Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion, 643
 Averbuch, S. D., *see* Felsted, R. L., 388

B

- Bäckström, I. T., *see* Marcusson, J. O., 121
 Baden, D. G., *see* Poli, M. A., 129
 Baker, S. P., and Posner, P. Irreversible binding of acetylcholine mustard to cardiac cholinergic muscarinic receptors, 411
 Balèstre, M.-N., *see* Guillemette, G., 544
 Balfour, C., *see* Halpert, J. R., 19
 Becker, C., *see* Kokubun, S., 571
 Beerman, T. A., *see* Grimwade, J. E., 358
 Benavides, J., *see* Marvizón, J. C. G., 590, 598
 Bend, J. R., *see* Mathews, J. M., 25
 Bender, P., *see* Mong, S., 235
 Blair, I. A., *see* Guengerich, F. P., 287
 Blumer, J. L., *see* Pellack-Walker, P., 42
 Brown, J. H., and Goldstein, D. Differences in muscarinic receptor reserve for inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis, 566
 Brown, J. H., *see* Harden, T. K., 200
 Brown, O. E., *see* Richards, R. G., 651
 Brown, S. R., *see* Puttfarcken, P., 81
 Brown, S. R., *see* Werling, L. L., 90
 Burgess, G. M., Dooley, R. K., McKinney, J. S., Nånberg, E., and Putney, J. W., Jr. Further studies on the interactions between the calcium mobilization and cyclic AMP pathways in guinea pig hepatocytes, 315
 Burke, R. E. Gallamine binding to muscarinic M1 and M2 receptors, studied by inhibition of [^3H]pirenzepine and [^3H]quinuclidinylbenzilate binding to rat brain membranes, 58

C

- Calvo, M. G., *see* Marvizón, J. C. G., 590, 598
 Cannon, N. J., *see* Sheldon, R. S., 617
 Cantin, M., *see* Meloche, S., 537
 Carlson, K. E., Woolkalis, M. J., Newhouse, M. G., and Manning, D. R. Fractionation of the β subunit common to guanine nucleotide-binding regulatory proteins with the cytoskeleton, 463
 Chang, R. S. L., Lotti, V. J., Chen, T. B., and Kunkel, K. A. Characterization of the binding of [^3H](\pm)-L-364,718: A new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors, 212
 Chen, K.-X., Gresh, N., and Pullman, B. A theoretical study of the comparative binding affinities of daunomycin derivatives to a double-stranded oligomeric DNA. Proposal for new high affinity derivatives, 279
 Chen, T. B., *see* Chang, R. S. L., 212
 Cheng, N., Payne, R. C., Kemp, W. E., Jr., and Traut, T. W. Homogeneous uridine kinase from Ehrlich ascites tumor: Substrate specificity and inhibition by bisubstrate analogs, 159

- Cheng, Y.-C., *see* Ueda, T., 149
 Chérot, P., Devin, J., Fournié-Zaluski, M. C., and Roques, B. P. Enkephalin-degrading dipeptidylaminopeptidase: Characterization of the active site and selective inhibition, 338
 Chi-Rosso, G., *see* Mong, S., 235
 Chisena, C. A., *see* Karle, J. M., 136
 Christinaki, H., *see* Servin, A. L., 379
 Christophe, J., *see* Waelbroeck, M., 305
 Clawson, R. E., *see* Felsted, R. L., 388
 Collins, A. C., *see* Marks, M. J., 427
 Conley, N. S., Yarbro, J. W., Ferrari, H. A., and Zeidler, R. B. Bleomycin increases superoxide anion generation by pig peripheral alveolar macrophages, 48
 Cook, M., *see* Hogaboom, G. K., 510
 Coon, M. J., *see* Ding, X., 370
 Cote, T. E., *see* Puttfarcken, P., 81
 Cowan, K. H., Goldsmith, M. E., Ricciardone, M., Levine, R., Rubalcaba, E., and Jolivet, J. Regulation of dihydrofolate reductase in human breast cancer cells and in mutant hamster cells transfected with a human dihydrofolate reductase minigene, 69
 Cowan, K. H., *see* Karle, J. M., 136
 Cox, B. M., *see* Puttfarcken, P., 81
 Cox, B. M., *see* Werling, L. L., 90
 Cragoe, E. J., Jr., *see* Simchowitz, L., 112
 Creese, I., *see* Norman, A. B., 96
 Cremel, G., *see* Rumbach, L., 270
 Crooke, S. T., *see* Hogaboom, G. K., 510
 Crooke, S. T., *see* Mong, S., 235
 Crowe, V. G., *see* Kauffman, R. F., 609
 Crump, B. L., *see* Ding, X., 370
 Csöregi, I., *see* Högberg, T., 345
 Curella, P., *see* Tank, A. W., 486, 497
 Cysyk, R. L., *see* Karle, J. M., 136

D

- Dahlgren, C., *see* Andersson, T., 437
 Dean, S. W., Gibson, N. W., and Tew, K. D. Selection of nitrogen mustard resistance in a rat tumor cell line results in loss of guanine- O^6 -alkyl transferase activity, 77
 DeCaprio, A. P. Mechanisms of *In Vitro* pyrrole adduct autoxidation in 2,5-hexanedione-treated protein, 452
 Degraw, J. I., *see* Ueda, T., 149
 De Léan, A., *see* Meloche, S., 537
 de Paulis, T., *see* Högberg, T., 345
 Devereux, T. R., *see* Domin, B. A., 296
 Devin, J., *see* Chérot, P., 338
 Ding, X., Koop, D. R., Crump, B. L., and Coon, M. J. Immunochemical identification of cytochrome P-450 isozyme 3a (P-450_{ALC}) in rabbit nasal and kidney microsomes and evidence for differential induction by alcohol, 370
 Djurhuus, R., *see* Svoldal, A., 154
 Domin, B. A., Devereux, T. R., and Philpot, R. M. The cytochrome P-450 monooxygenase system of rabbit lung: Enzyme components, activities, and induction in the nonciliated bronchiolar epithelial (Clara) cell, alveolar type II cell, and alveolar macrophage, 296
 Dooley, R. K., *see* Burgess, G. M., 315
 Dudycz, L. W., *see* Kelleher, D. J., 603
 Duff, H. J., *see* Sheldon, R. S., 617
 Dutschman, G. E., *see* Ueda, T., 149

E

- Eastmond, D. A., Smith, M. T., Ruza, L. O., and Ross, D. Metabolic activation of phenol by human myeloperoxidase and horseradish peroxidase, 674
 El Tayar, N., *see* Kilpatrick, G. J., 226
 Entman, M. L., *see* Tsokos-Kuhn, J. O., 444
 Escher, E., *see* Guillemette, G., 544
 Ezumi, K., *see* Yamakawa, M., 585

F

- Feldman, R. D., McArdle, W., and Lai, C. Phenylarsine oxide inhibits agonist-induced changes in photolabeling but not agonist-induced desensitization of the β -adrenergic receptor, 459
 Felsted, R. L., Glover, C. J., Clawson, R. E., and Averbuch, S. D. Rat heart anthracycline-binding polypeptides identified by photoaffinity labeling, 388
 Ferrari, H. A., *see* Conley, N. S., 48
 Flynn, D. D. and Potter, L. T. Effects of solubilization on the distinct binding properties of muscarinic receptors from rabbit hippocampus and brainstem, 193
 Fok, K. F., *see* Michener, M. L., 552
 Fournié-Zaluski, M. C., *see* Chérot, P., 338

G

- Gaillard, R. C., *see* Jard, S., 171
 Gee, K. W., Lawrence, L. J., and Yamamura, H. I. Modulation of the chloride ionophore by benzodiazepine receptor ligands: Influence of *v*-aminobutyric acid and ligand efficacy, 218
 Gibson, N. W., *see* Dean, S. W., 77
 Gierse, J. K., *see* Michener, M. L., 552
 Gillard, M., *see* Waelbroeck, M., 305
 Gillison, M. L., *see* Richards, R. G., 651
 Glover, C. J., *see* Felsted, R. L., 388
 Gnegy, M. E., *see* Mickevicius, C. K., 469
 Goldsmith, M. E., *see* Cowan, K. H., 69
 Goldstein, D., *see* Brown, J. H., 566
 Gómez, A. R., *see* Marvizón, J. C. G., 590, 598
 Grab, L. A., *see* Ortiz de Montellano, P. R., 666
 Gresh, N., *see* Chen, K.-X., 279
 Grimwade, J. E., and Beerman, T. A. Measurement of bleomycin, neocarzinostatin, and auromomycin cleavage of cell-free and intracellular simian virus 40 DNA and chromatin, 358
 Grol, C. J., *see* Johansson, A. M., 258
 Guengerich, F. P., Müller-Enoch, D., and Blair, I. A. Oxidation of quinidine by human liver cytochrome P-450, 287
 Guillemette, G., Guillon, G., Marie, J., Balèstre, M.-N., Escher, E., and Jard, S. High yield photoaffinity labeling of angiotensin II receptors, 544
 Guillon, G., *see* Guillemette, G., 544
 Guillon, G., *see* Jard, S., 171
 Gupta, R. S. Cross-resistance of nocodazole-resistant mutants of CHO cells toward other microtubule inhibitors: Similar mode of action of benzimidazole carbamate derivatives and NSC 181928 and TN-16, 142

H

- Hacksell, U., *see* Johansson, A. M., 258
 Haga, N., *see* Yamakawa, M., 585
 Halpert, J. R., Balfour, C., Miller, N. E., and Kaminsky, L. S. Dichloromethyl compounds as mechanism-based inactivators of rat liver cytochrome P-450 *in vitro*, 19
 Ham, L., *see* Tank, A. W., 486, 497
 Handler, J. A., *see* Olson, M. J., 520
 Harden, T. K., Heng, M. M., and Brown, J. H. Receptor reserve in the calcium-dependent cyclic AMP response of astrocytoma cells to muscarinic receptor stimulation: Demonstration by agonist-in-

duced desensitization, receptor inactivation, and phorbol ester treatment, 200

- Harrison, J. K., *see* Mickevicius, C. K., 469
 Heng, M. M., *see* Harden, T. K., 200
 Herz, J. M., *see* Palma, A., 243
 Hinson, J. A., *see* Potter, D. W., 33
 Hoffman, K., *see* Mong, S., 235
 Hoffman, P. L., Moses, F., Luthin, G. R., and Tabakoff, B. Acute and chronic effects of ethanol on receptor-mediated phosphatidylinositol 4,5-bisphosphate breakdown in mouse brain, 13
 Hogaboom, G. K., Cook, M., Newton, J. F., Varrichio, A., Shorr, R. G. L., Sarau, H. M., and Crooke, S. T. Purification, characterization, and structural properties of a single protein from rat basophilic leukemia (RBL-1) cells possessing 5-lipoxygenase and leukotriene A₄ synthase activities, 510
 Högborg, T., Råmsby, S., de Paulis, T., Stensland, B., Csöregi, I., and Wägnér, A. Solid state conformations and antidopaminergic effects of remoxipride hydrochloride and a closely related salicylamide, FLA 797, in relation to dopamine receptor models, 345
 Hom, B. E., *see* Tsai, S.-C., 274
 Hong, J.-S., *see* Sivam, S. P., 186
 Howell, S. B., *see* Andrews, P. A., 643

J

- Jacobsen, N., *see* McCluskey, S. A., 352
 Jard, S., Gaillard, R. C., Guillon, G., Marie, J., Schoenenberg, P., Muller, A. F., Manning, M., and Sawyer, W. H. Vasopressin antagonists allow demonstration of a novel type of vasopressin receptor in the rat adenohypophysis, 171
 Jard, S., *see* Guillemette, G., 544
 Jarvis, S. M. Nitrobenzylthioinosine-sensitive nucleoside transport system: Mechanism of inhibition by dipyrindamole, 659
 Jenner, P., *see* Kilpatrick, G. J., 226
 Johansson, A. M., Karlén, A., Grol, C. J., Sundell, S., Kenne, L., and Hacksell, U. Dopaminergic 2-aminotetralins: Affinities for dopamine D₂-receptors, molecular structures, and conformational preferences, 258
 Johnson, G. L., *see* Kelleher, D. J., 603
 Johnson, M. D., *see* Wang, J. K. T., 639
 Jolivet, J., *see* Cowan, K. H., 69

K

- Kamata, S., *see* Yamakawa, M., 585
 Kaminsky, L. S., *see* Halpert, J. R., 19
 Karle, J. M., Cowan, K. H., Chisena, C. A., and Cysyk, R. L. Uracil nucleotide synthesis in a human breast cancer cell line (MCF-7) and in two drug-resistant sublines that contain increased levels of enzymes of the *de Novo* pyrimidine pathway, 136
 Karlén, A., *see* Johansson, A. M., 258
 Kauffman, R. F., Crowe, V. G., Utterback, B. G., and Robertson, D. W. LY195115: A potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum, 609
 Kelleher, D. J., Dudycz, L. W., Wright, G. E., and Johnson, G. L. Ability of guanine nucleotide derivatives to bind and activate bovine transducin, 603
 Kemp, W. E., Jr., *see* Cheng, N., 159
 Kenne, L., *see* Johansson, A. M., 258
 Kilpatrick, G. J., El Tayar, N., Van De Waterbeemd, H., Jenner, P., Testa, B., and Marsden, C. D. The thermodynamics of agonist and antagonist binding to dopamine D-2 receptors, 226
 Kim, D. and Smith, T. W. Inhibition of multiple trans-sarcolemmal cation flux pathways by dichlorobenzamil in cultured chick heart cells, 164
 Kinnier, W. J., *see* Noronha-Blob, L., 526
 Klotz, K.-N., *see* Lohse, M. J., 403
 Kokubun, S., Prod'hom, B., Becker, C., Porzig, H., and Reuter, H. Studies on Ca channels in intact cardiac cells: Voltage-dependent

- effects and cooperative interactions of dihydropyridine enantiomers, 571
- Kontoghiorghes, G. J. Orally active α -ketohydroxypyridine iron chelators: Studies in mice, 670
- Koop, D. R., *see* Ding, X., 370
- Kufe, D., *see* Mitchell, T., 398
- Kunkel, K. A., *see* Chang, R. S. L., 212
- L**
- Lai, C., *see* Feldman, R. D., 459
- Lawrence, L. J., *see* Gee, K. W., 218
- Levine, R., *see* Cowan, K. H., 69
- Lew, D. P., *see* Andersson, T., 437
- Lohse, M. J., Klotz, K.-N., and Schwabe, U. Agonist photoaffinity labeling of A_1 adenosine receptors: Persistent activation reveals spare receptors, 403
- Lotti, V. J., *see* Chang, R. S. L., 212
- Lowe, V. C., *see* Noronha-Blob, L., 526
- Luthin, G. R., *see* Hoffman, P. L., 13
- Luttrell, L. M., and Rogol, A. D. Hexose-independent activation of glycogen synthase and pyruvate dehydrogenase by insulin is dissociated in the mouse BC₃H-1 cell line, 624
- M**
- Mai, M. S., *see* Michener, M. L., 552
- Maksay, G., and Simonyi, M. Kinetic regulation of convulsant (TBPS) binding by GABAergic agents, 321
- Manganiello, V. C., *see* Tsai, S.-C., 274
- Manning, D. R., *see* Carlson, K. E., 463
- Manning, M., *see* Jard, S., 171
- Marcusson, J. O., Bäckström, I. T., and Ross, S. B. Single-site model of the neuronal 5-hydroxytryptamine uptake and imipramine-binding site, 121
- Marescaux, C. A., *see* Rumbach, L., 270
- Marie, J., *see* Guillemette, G., 544
- Marie, J., *see* Jard, S., 171
- Marks, G. S., *see* McCluskey, S. A., 352
- Marks, M. J., Stitzel, J. A., Romm, E., Wehner, J. M., and Collins, A. C. Nicotinic binding sites in rat and mouse brain: Comparison of acetylcholine, nicotine, and α -bungarotoxin, 427
- Marsden, C. D., *see* Kilpatrick, G. J., 226
- Marvizón, J. C. G., Calvo, M. G., Vázquez, J., Mayor, F., Jr., Gómez, A. R., Valdivieso, F., and Benavides, J. Activation and inhibition of ³H-strychnine binding to the glycine receptor by Eccles' anions: Modulatory effects of cations, 598
- Marvizón, J. C. G., Vázquez, J., Calvo, M. G., Mayor, F., Jr., Gómez, A. R., Valdivieso, F., and Benavides, J. The glycine receptor: Pharmacological studies and mathematical modeling of the allosteric interaction between the glycine- and strychnine-binding sites, 590
- Masters, B. S. S., *see* Poulsen, L. L., 680
- Mathews, J. M. and Bend, J. R. *N*-alkylaminobenzotriazoles as isozyme-selective suicide inhibitors of rabbit pulmonary microsomal cytochrome P-450, 25
- Matsui, T., *see* Yamakawa, M., 585
- Mayor, F., Jr., *see* Marvizón, J. C. G., 590, 598
- McArdle, W., *see* Feldman, R. D., 459
- McCluskey, S. A., Marks, G. S., Sutherland, E. P., Jacobsen, N., and Ortiz de Montellano, P. R. Ferrochelatase-inhibitory activity and *N*-alkylprotoporphyrin formation with analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine (DDC) containing extended 4-alkyl groups: Implications for the active site of ferrochelatase, 352
- McGonigle, P., Neve, K. A., and Molinoff, P. B. A quantitative method of analyzing the interaction of slightly selective radioligands with multiple receptor subtypes, 329
- McKinney, J. S., *see* Burgess, G. M., 315
- McKinney, M. and Richelson, E. Muscarinic responses and binding in a murine neuroblastoma clone (N1E-115): Cyclic GMP formation is mediated by a low affinity agonist-receptor conformation and cyclic AMP is mediated by a high affinity agonist-receptor conformation, 207
- McLarnon, J. G., Saint, D. A., and Quastel, D. M. J. The actions of dimethyl sulfoxide on neuromuscular transmission, 631
- Meloche, S., Ong, H., Cantin, M., and De Léan, A. Molecular characterization of the solubilized atrial natriuretic factor receptor from bovine adrenal zona granulosa, 537
- Mende, T. J., *see* Poli, M. A., 129
- Micheletti, G., *see* Rumbach, L., 270
- Michener, M. L., Gierse, J. K., Seetharam, R., Fok, K. F., Olins, P. O., Mai, M. S., and Needleman, P. Proteolytic processing of atriopeptin prohormone *In Vivo* and *In Vitro*, 552
- Mickevicius, C. K., Harrison, J. K., and Gnegy, M. E. Effect of cholera toxin on the activation of adenylate cyclase by calmodulin in bovine striatum, 469
- Miller, J., *see* Mong, S., 235
- Miller, N. E., *see* Halpert, J. R., 19
- Miller, R. C., *see* Schoeffter, P., 53
- Miller, R. J., *see* Thayer, S. A., 505
- Mitchell, J. R., *see* Tsokos-Kuhn, J. O., 444
- Mitchell, T., Sariban, E., and Kufe, D. Effects of 1- β -D-arabinofuranosylcytosine on proto-oncogene expression in human U-937 cells, 398
- Molinoff, P. B., *see* McGonigle, P., 329
- Molinoff, P. B., *see* Neve, K. A., 104
- Mong, S., Chi-Rosso, G., Miller, J., Hoffman, K., Razgaitis, K. A., Bender, P., and Crooke, S. T. Leukotriene B₄ induces formation of inositol phosphates in rat peritoneal polymorphonuclear leukocytes, 235
- Morgan, J. I., *see* Wang, J. K. T., 646
- Moses, F., *see* Hoffman, P. L., 13
- Mosimann, W., *see* Tachikawa, E., 476
- Moss, J., *see* Tsai, S.-C., 274
- Muller, A. F., *see* Jard, S., 171
- Müller-Enoch, D., *see* Guengerich, F. P., 287
- Murphy, M. P., *see* Andrews, P. A., 643
- Murphy, S. N., *see* Thayer, S. A., 505
- Mutet, C., *see* Rumbach, L., 270
- N**
- Nair, M. G., *see* Ueda, T., 149
- Nakai, H., *see* Yamakawa, M., 585
- Nänberg, E., *see* Burgess, G. M., 315
- Near, J. A. [³H]Dihydrotrabenazine binding to bovine striatal synaptic vesicles, 252
- Needleman, P., *see* Michener, M. L., 552
- Nerme, V., Severne, Y., Abrahamsson, T., and Vauquelin, G. Spontaneous coupling of the β -adrenergic receptor to N_s in mammalian cardiac membranes, 1
- Neve, K. A., *see* McGonigle, P., 329
- Neve, K. A. and Molinoff, P. B. Turnover of β_1 - and β_2 -adrenergic receptors after down-regulation or irreversible blockade, 104
- Newhouse, M. G., *see* Carlson, K. E., 463
- Newton, J. F., *see* Hogaboom, G. K., 510
- Norman, A. B. and Creese, I. Effects of *in vivo* and *in vitro* treatments with *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain, 96
- Noronha-Blob, L., Lowe, V. C., Kinnier, W. J., and U'Prichard, D. C. N_i -Coupled receptors in cultured neural hybrid cells: Cell specificity for dibutyl cyclic AMP-induced down-regulation but not morphological differentiation, 526
- O**
- Olins, P. O., *see* Michener, M. L., 552
- Olson, M. J., Handler, J. A., and Thurman, R. G. Mechanism of zone-specific hepatic steatosis caused by valproate: Inhibition of ketogenesis in periportal regions of the liver lobule, 520
- Ong, H., *see* Meloche, S., 537

- Ortiz de Montellano, P. R., and Grab, L. A. Cooxidation of styrene by horseradish peroxidase and glutathione, 666
 Ortiz de Montellano, P. R., see McCluskey, S. A., 352

P

- Palma, A., Herz, J. M., Wang, H. H., and Taylor, P. Association of a spin-labeled local anesthetic with the allosterically coupled non-competitive inhibitor site on the acetylcholine receptor, 243
 Paul, S. M., see Schwartz, R. D., 419
 Payne, R. C., see Cheng, N., 159
 Pellack-Walker, P. and Blumer, J. L. DNA damage in L5178YS cells following exposure to benzene metabolites, 42
 Philpot, R. M., see Domin, B. A., 296
 Poli, M. A., Mende, T. J., and Baden, D. G. Brevetoxins, unique activators of voltage-sensitive sodium channels, bind to specific sites in rat brain synaptosomes, 129
 Porzig, H., see Kokubun, S., 571
 Posner, P., see Baker, S. P., 411
 Potter, D. W. and Hinson, J. A. Reactions of *N*-acetyl-*p*-benzoquinone imine with reduced glutathione, acetaminophen, and NADPH, 33
 Potter, L. T., see Flynn, D. D., 193
 Poulsen, L. L., Taylor, K., Williams, D. E., Masters, B. S. S., and Ziegler, D. M. Substrate specificity of the rabbit lung flavin-containing monooxygenase for amines: Oxidation products of primary alkylamines, 680
 Pozzan, T., see Andersson, T., 437
 Prod'homme, B., see Kokubun, S., 571
 Puig, J. F., and Tephly, T. R. Isolation and purification of rat liver morphine and UDP-glucuronosyltransferase, 558
 Pullman, B., see Chen, K.-X., 279
 Putney, J. W., Jr., see Burgess, G. M., 315
 Puttfarcken, P., see Werling, L. L., 90
 Puttfarcken, P., Werling, L. L., Brown, S. R., Cote, T. E., and Cox, B. M. Sodium regulation of agonist binding at opioid receptors. I. Effects of sodium replacement on binding at μ - and δ -type receptors in 7315c and NG108-15 cells and cell membranes, 81

Q

- Quastel, D. M. J., see McLarnon, J. G., 631

R

- Rämsby, S., see Högborg, T., 345
 Razgaitis, K. A., see Mong, S., 235
 Reuter, H., see Kokubun, S., 571
 Ricciardone, M., see Cowan, K. H., 69
 Richards, R. G., Brown, O. E., Gillison, M. L., and Sedwick, W. D. Drug concentration-dependent DNA lesions are induced by the lipid-soluble antifolate, piritrexim (BW301U), 651
 Richelson, E., see McKinney, M., 207
 Robberecht, P., see Waelbroeck, M., 305
 Robertson, D. W., see Kauffman, R. F., 609
 Rogol, A. D., see Luttrell, L. M., 624
 Romm, E., see Marks, M. J., 427
 Roques, B. P., see Chérot, P., 338
 Ross, D., see Eastmond, D. A., 674
 Ross, S. B., see Marcusson, J. O., 121
 Rubalcaba, E., see Cowan, K. H., 69
 Rumbach, L., Mutet, C., Cremel, G., Marescaux, C. A., Micheletti, G., Warter, J. M., and Waksman, A. Effects of sodium valproate on mitochondrial membranes: Electron paramagnetic resonance and transmembrane protein movement studies, 270
 Ruzo, L. O., see Eastmond, D. A., 674

S

- Saint, D. A., see McLarnon, J. G., 631
 Sarau, H. M., see Hogaboom, G. K., 510
 Sariban, E., see Mitchell, T., 398
 Sawyer, W. H., see Jard, S., 171

- Scheibel, L. W., and Stanton, G. G. Antimalarial activity of selected aromatic chelators. IV. Cation uptake by *Plasmodium falciparum* in the presence of oxines and siderochromes, 364
 Schenkman, J. B., see Tamburini, P. P., 178
 Schoeffter, P. and Miller, R. C. Role of sodium-calcium exchange and effects of calcium entry blockers on endothelial-mediated responses in rat isolated aorta, 53
 Schoenenberg, P., see Jard, S., 171
 Schwabe, U., see Lohse, M. J., 403
 Schwartz, R. D., Suzdak, P. D., and Paul, S. M. γ -Aminobutyric acid (GABA)- and barbiturate-mediated $^{36}\text{Cl}^-$ uptake in rat brain synaptoneurosome: Evidence for rapid desensitization of the GABA receptor-coupled chloride ion channel, 419
 Sedwick, W. D., see Richards, R. G., 651
 Seetharam, R., see Michener, M. L., 552
 Servin, A. L., Christinaki, H., and Viel, C. Identification and molecular characterization of the isoquinoline rat intestinal binding site using 6,7-dimethoxy-4-(4'-amino-3'-[^{125}I]iodobenzyl) isoquinoline, 379
 Severne, Y., see Nerme, V., 1
 Sheldon, R. S., Cannon, N. J., and Duff, H. J. Binding of [^3H]batrachotoxin A benzoate to specific sites on rat cardiac sodium channels, 617
 Shiro, M., see Yamakawa, M., 585
 Shorr, R. G. L., see Hogaboom, G. K., 510
 Simasko, S. M., Soares, J. R., and Weiland, G. A. Two components of carbamylcholine-induced loss of nicotinic acetylcholine receptor function in the neuronal cell line PC12, 6
 Simchowitz, L. and Cragoe, E. J., Jr. Inhibition of chemotactic factor-activated Na^+/H^+ exchange in human neutrophils by analogues of amiloride: Structure-activity relationships in the amiloride series, 112
 Simonyi, M., see Maksay, G., 321
 Sirotnak, F. M., see Ueda, T., 149
 Sivam, S. P., Strunk, C., Smith, D. R., and Hong, J.-S. Proenkephalin-A gene regulation in the rat striatum: Influence of lithium and haloperidol, 186
 Smith, C. V., see Tsokos-Kuhn, J. O., 444
 Smith, D. R., see Sivam, S. P., 186
 Smith, M. T., see Eastmond, D. A., 674
 Smith, T. W., see Kim, D., 164
 Soares, J. R., see Simasko, S. M., 6
 Spector, S., see Wang, J. K. T., 639
 Stanton, G. G., see Scheibel, L. W., 364
 Stendahl, O., see Andersson, T., 437
 Stensland, B., see Högborg, T., 345
 Stitzel, J. A., see Marks, M. J., 427
 Strunk, C., see Sivam, S. P., 186
 Sundell, S., see Johansson, A. M., 258
 Sutherland, E. P., see McCluskey, S. A., 352
 Suzdak, P. D., see Schwartz, R. D., 419
 Svandal, A., Djurhuus, R., and Ueland, P. M. Disposition of homocysteine and S-3-deazaadenosylhomocysteine in cells exposed to 3-deazaadenosine, 154

T

- Tabakoff, B., see Hoffman, P. L., 13
 Tachikawa, E., Tank, A. W., Yanagihara, N., Mosimann, W., and Weiner, N. Phosphorylation of tyrosine hydroxylase on at least three sites in rat pheochromocytoma PC12 cells treated with 56 M K^+ : Determination of the sites on tyrosine hydroxylase phosphorylated by cyclic AMP-dependent and calcium/calmodulin-dependent protein kinases, 476
 Tamburini, P. P. and Schenkman, J. B. Differences in the mechanism of functional interaction between NADPH-cytochrome P-450 reductase and its redox partners, 178
 Tank, A. W., Curella, P., and Ham, L. Induction of mRNA for tyrosine hydroxylase by cyclic AMP and glucocorticoids in a rat pheochromocytoma cell line: Evidence for the regulation of tyrosine hy-

- droxylase synthesis by multiple mechanisms in cells exposed to elevated levels of both inducing agents, 497
- Tank, A. W., Ham, L., and Curella, P. Induction of tyrosine hydroxylase by cyclic AMP and glucocorticoids in a rat pheochromocytoma cell line: Effect of the inducing agents alone or in combination on the enzyme levels and rate of synthesis of tyrosine hydroxylase, 486
- Tank, A. W., *see* Tachikawa, E., 476
- Tate, C. A., *see* Tsokos-Kuhn, J. O., 444
- Taylor, K., *see* Poulsen, L. L., 680
- Taylor, P., *see* Palma, A., 243
- Tephly, T. R., *see* Puig, J. F., 558
- Testa, B., *see* Kilpatrick, G. J., 226
- Tew, K. D., *see* Dean, S. W., 77
- Thayer, S. A., Murphy, S. N., and Miller, R. J. Widespread distribution of dihydropyridine-sensitive calcium channels in the central nervous system, 505
- Thurman, R. G., *see* Olson, M. J., 520
- Traut, T. W., *see* Cheng, N., 159
- Tsai, S.-C., Adamik, R., Hom, B. E., Manganiello, V. C., and Moss, J. Effects of nitroprusside on the bradykinin responsiveness of human fibroblasts, 274
- Tsokos-Kuhn, J. O., Smith, C. V., Mitchell, J. R., Tate, C. A., and Entman, M. L. Evidence for increased membrane permeability of plasmalemmal vesicles from livers of phenobarbital-induced CCL₄-intoxicated rats, 444
- U**
- Ueda, T., Dutschman, G. E., Nair, M. G., Degraw, J. I., Sirotinak, F. M., and Cheng, Y.-C. Inhibitory action of 10-deazaaminopterin and their polyglutamates on human thymidylate synthase, 149
- Ueland, P. M., *see* Svardal, A., 154
- U'Prichard, D. C., *see* Noronha-Blob, L., 526
- Utterback, B. G., *see* Kauffman, R. F., 609
- V**
- Valdivieso, F., *see* Marvizón, J. C. G., 590, 598
- Van De Waterbeemd, H., *see* Kilpatrick, G. J., 226
- Varrichio, A., *see* Hogaboom, G. K., 510
- Vauquelin, G., *see* Nerme, V., 1
- Vázquez, J., *see* Marvizón, J. C. G., 590
- Vázquez, J., *see* Marvizón, J. C. G., 598
- Viel, C., *see* Servin, A. L., 379
- W**
- Waelbroeck, M., Gillard, M., Robberecht, P., and Christophe, J. Kinetic studies of [³H]-N-methylscopolamine binding to muscarinic receptors in the rat central nervous system: Evidence for the existence of three classes of binding sites, 305
- Wagner, A., *see* Högberg, T., 345
- Waksman, A., *see* Rumbach, L., 270
- Wang, H. H., *see* Palma, A., 243
- Wang, J. K. T., Johnson, M. D., Morgan, J. I., and Spector, S. Vitamin D₃ derivatives inhibit the differentiation of friend erythroleukemia cells, 639
- Warter, J. M., *see* Rumbach, L., 270
- Wehner, J. M., *see* Marks, M. J., 427
- Weiland, G. A., *see* Simasko, S. M., 6
- Weiner, N., *see* Tachikawa, E., 476
- Werling, L. L., Brown, S. R., Puttfarcken, P., and Cox, B. M. Sodium regulation of agonist binding at opioid receptors. II. Effects of sodium replacement on opioid binding in guinea pig cortical membranes, 90
- Werling, L. L., *see* Puttfarcken, P., 81
- Williams, D. E., *see* Poulsen, L. L., 680
- Woolkalis, M. J., *see* Carlson, K. E., 463
- Wright, G. E., *see* Kelleher, D. J., 603
- Y**
- Yamakawa, M., Ezumi, K., Shiro, M., Nakai, H., Kamata, S., Matsui, T., and Haga, N. Relationships of the molecular structure of aldosterone derivatives with their binding affinity for mineralocorticoid receptor, 585
- Yamamura, H. I., *see* Gee, K. W., 218
- Yanagihara, N., *see* Tachikawa, E., 476
- Yarbro, J. W., *see* Conley, N. S., 48
- Z**
- Zeidler, R. B., *see* Conley, N. S., 48
- Ziegler, D. M., *see* Poulsen, L. L., 680

SUBJECT INDEX FOR VOLUME 30

A

Acetaminophen, reduced glutathione and NADPH, reactions with *N*-acetyl-*p*-benzoquinone imine, 33

Acetylcholine, binding sites, brain, 427

Acetylthylcholine mustard, irreversible binding, cardiac cholinergic muscarinic receptors, 411

N-Acetyl-*p*-benzoquinone imine, reactions, reduced glutathione, acetaminophen and NADPH, 33

Adenohypophysis, vasopressin antagonists, novel vasopressin receptor (rat), 171

Adenosine analogues, homocysteine and *S*-3-deazaadenosylhomocysteine, metabolic effects, 154

Adenylate cyclase
activation by calmodulin, effect of cholera toxin, bovine striatum, 469

β -adrenergic receptors, photolabeling changes, phenylarsine oxide inhibition, 459

guanine nucleotide-binding regulatory proteins, fractionation of the β subunit, 463

inhibition, phosphoinositide hydrolysis stimulation, muscarinic receptor reserve (chick), 566

stimulating regulatory component, spontaneous coupling of β -adrenergic receptor, mammalian cardiac membranes (rat, cat, guinea pig), 1

ADP-ribosylation, effect of cholera toxin, adenylate cyclase activation by calmodulin, bovine striatum, 469

Adrenal zona glomerulosa, receptor characterization, atrial natriuretic factor, 537

Alcohol, cytochrome P-450 isozyme 3a, nasal and kidney microsomes (rabbit), 370

Aldosterone, derivatives, binding affinity, mineralocorticoid receptor, 585

Alkylamines, flavin-containing monooxygenase, lung (rabbit), 680

N-Alkylaminobenzotriazoles, isozyme-selective suicide inhibitors, pulmonary microsomal cytochrome P-450 (rat, rabbit), 25

Alkylating agents, turnover of β_1 - and β_2 -adrenergic receptors, down-regulation or irreversible blockade (rat), 104

N-Alkylprotoporphyrin, implications for ferrochelatase active site, 352

Amiloride, analogues, inhibition of sodium-hydrogen exchange, neutrophils, 112

γ -Aminobutyric acid, GABAergic agents, kinetics of *t*-butylbicyclophosphorothionate binding (rat), 321

γ -Aminobutyric acid
benzodiazepine receptor ligands, chloride ionophore, ligand efficacy (rat), 218

chloride ion uptake in brain synaptoneurosomes, desensitization of GABA receptor, 419

2-Aminotetralins, dopamine D-2 receptor affinities, molecular structures, conformational preferences, 258

Anesthetics, spin-labeled, acetylcholine receptor, 243

ANF1-126, atriopeptin prohormone, proteolytic processing (rabbit), 552

Angiotensin II, receptors, high yield photoaffinity labeling (rat), 544

Anions, Eccles', strychnine binding to glycine receptor, cation modulation, 598

Anthracyclines, binding, polypeptides, heart, 388

Antiarrhythmic drugs, batrachotoxin A benzoate, binding, cardiac sodium channels (rat), 617

Anticonvulsants, benzodiazepine receptor ligands, chloride ionophore, γ -aminobutyric acid (rat), 218

Antiepileptics, sodium valproate, mitochondrial membranes, trans-

membrane protein movement studies (rat), 270

Antimalarials, selected aromatic chelators, cation uptake, *Plasmodium falciparum*, 364

Antipsychotics, remoxipride hydrochloride and FLA 797, solid state conformations, antidopaminergic effects, 345

Antitumor properties, comparative binding affinities, daunomycin derivatives, double-stranded oligomeric DNA, 279

Aorta, sodium-calcium exchange and calcium entry blockers, endothelial-mediated responses (rat), 53

1- β -D-Arabinofuranosylcytosine, effects on protooncogene expression, U937 cells, 398

Arachidonate 5-lipoxygenase, basophilic leukemia cells (rat), 510

Astrocytoma cells, receptor reserve, muscarinic receptors, 200

Atria, cardiac cholinergic muscarinic receptors, acetylthylcholine mustard binding, 411

Atrial natriuretic factor, receptor characterization, bovine adrenal zona glomerulosa, 537

Atriopeptin, prohormone, proteolytic processing (rabbit), 552

Auromomycin, measurement of cleavage, Simian virus 40 DNA and chromatin, 358

Autoxidation, pyrrole adduct, 2,5-hexanedione-treated protein, 452

Alveolar type II cells, cytochrome P-450, monooxygenase system (rabbit), 296

B

Barbiturates, chloride ion uptake in brain synaptoneurosomes, GABA receptor desensitization, 419

Basal ganglia, lithium and haloperidol, proenkephalin-A gene regulation, striatum (rat), 186

Batrachotoxin A benzoate, binding, cardiac sodium channels (rat), 617

Benzamides, remoxipride hydrochloride and FLA 797, solid state conformations, antidopaminergic effects, 345

Benzene, metabolic activation of phenol, myeloperoxidase and horseradish peroxidase, 674

Benzene metabolites, exposed L5178YS cells, DNA damage, 42

Benzimidazole carbamate, derivatives, nocodazole-resistant mutants and CHO cells, microtubule inhibitors, 142

Benzodiazepine, receptor ligands, chloride ionophore, γ -aminobutyric acid (rat), 218

N-Benzylaminobenzotriazole, pulmonary microsomal P-450, *N*-alkylaminobenzotriazoles, suicide inhibitors (rat, rabbit), 25

Bicuculline methochloride, GABAergic agents, kinetics of *t*-butylbicyclophosphorothionate binding (rat), 321

Binding affinities, comparison, daunomycin derivatives, double-stranded oligomeric DNA, 279

4,4'-Biphenol, metabolic activation of phenol, myeloperoxidase and horseradish peroxidase, 674

Bisubstrate analogues, homogenous uridine kinase, Ehrlich ascites tumor, 159

Bleomycin
neocarzinostatin and auromomycin cleavage, Simian virus 40 DNA and chromatin, 358

superoxide anion generation, peripheral alveolar macrophages (pig), 48

Bone marrow, DNA damage in L5178YS cells, exposure to benzene metabolites, 42

Bradykinin, nitroprusside and, effects on fibroblasts, 274

Brain
acute and chronic effects of ethanol, phosphatidylinositol 4,5-bisphosphate breakdown (mouse), 13

binding sites, comparison of acetylcholine, nicotine and α -bungarotoxin

Brain—continued

- toxin, 427
- gallamine binding, muscarinic M1 and M2 receptors (rat), 58
- neuronal serotonin uptake, imipramine-binding site, single-site model (rat), 121
- putative muscarinic receptor subtypes, *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline treatment (rat), 96
- synaptosomes, brevetoxins, sodium channel activation (rat), 129
- Brainstem, hippocampus and, muscarinic receptors, effect of solubilization (rabbit), 193
- Brevetoxins, sodium channel activation, brain synaptosomes (rat), 129
- Bronchiolar epithelial cells, cytochrome P-450, monooxygenase system (rabbit), 296
- α -Bungarotoxin, binding sites, brain, 427
- t*-Butylbicyclopophosphorothionate, kinetics of binding, GABAergic agents (rat), 321
- t*-Butylcyclopophosphorothionate, benzodiazepine receptor ligands, chloride ionophore, γ -aminobutyric acid (rat), 218
- BW301U, piritrexim, induced DNA lesions, 651

C

Calcium

- entry blockers, sodium exchange, endothelial-mediated responses in aorta (rat), 53
- influx, fMet-Leu-Phe receptor, neutrophils, 437
- liver plasmalemmal vesicles, membrane permeability, 444
- mobilization, cyclic AMP pathways, hepatocytes (guinea pig), 315
- muscarinic receptor stimulation, receptor reserve, astrocytoma cells, 200
- phosphorylation of tyrosine hydroxylase, pheochromocytoma PC12 cells, 476
- Calcium channels
 - dihydropyridine-sensitive, distribution, central nervous system, 505
 - inhibited cation flux pathways, dichlorobenzamil (chick), 164
 - intact cardiac cells, dihydropyridine enantiomers (rat), 571

Calmodulin

- adenylate cyclase activation, effect of cholera toxin, bovine striatum, 469
- phosphorylation of tyrosine hydroxylase, pheochromocytoma PC12 cells, 476
- Carbachol, multiple muscarinic receptors, neuroblastoma cells (mouse), 207
- Carbamylcholine, induced loss, nicotinic acetylcholine receptor function, PC12 cells, 6
- Carcinogenesis, DNA damage in L5178YS cells, exposure to benzene metabolites, 42
- Carcinoma, ovarian, glutathione-modulated cytotoxicity, cisplatin and melphalan, 643
- Cardiac cells, calcium channels, dihydropyridine enantiomers (rat), 571
- Cardiac membranes, mammalian, spontaneous coupling to N_S , β -adrenergic receptor (rat, cat, guinea pig), 1
- Cardiotonic agents, LY195115, inhibitor of cyclic nucleotide phosphodiesterase, sarcoplasmic reticulum, 609

Catecholamines, dihydrotetrabenazine binding, striatal synaptic vesicle (bovine), 252

- Cation, flux pathways, dichlorobenzamil (chick), 164
- Cations, modulation, strychnine binding to glycine receptor, Eccles' anions, 598
- Caudate nucleus, effect of cholera toxin, adenylate cyclase activation by calmodulin, bovine striatum, 469

Central nervous system

- distribution, dihydropyridine-sensitive calcium channels, 505
- muscarinic receptor classes, brain (rat), 305
- Cerebellum, muscarinic receptor classes (rat), 305
- Chelators, aromatic, antimalarial activity, 364
- Chloramphenicol, cytochrome P-450, mechanism-based inactivators, liver (rat), 19

Chloride, ion channel, uptake in brain synaptoneurosomes, GABA receptor desensitization, 419

Chloride ionophore

benodiazepine receptor ligands, γ -aminobutyric acid, ligand efficacy (rat), 218

GABAergic agents, kinetics of *t*-butylbicyclopophosphorothionate binding (rat), 321

CHO cells, nocodazole-resistant mutants, cross-resistance, microtubule inhibitors, 142

Cholecystokinin, peripheral receptors, nonpeptide radioligand (rat), 212

Cholera toxin, adenylate cyclase activation, calmodulin, 469

Chromatin, Simian virus 40 DNA and, bleomycin, neocarzinostatin and auromomycin cleavage, 358

Cisplatin, melphalan and, glutathione-modulated cytotoxicity, ovarian carcinoma and L1210 cells, 643

c-myc, 1- β -D-arabinofuranosylcytosine, effect on expression, U937 cells, 398

Cortex, muscarinic receptor classes (rat), 305

Cortical membranes, sodium regulation, opioid receptor agonist binding (guinea pig), 90

Cyclic AMP

- glucocorticoids and
 - induction of mRNA, tyrosine hydroxylase, 497
 - induction of tyrosine hydroxylase, pheochromocytoma cells, 486
- multiple muscarinic receptors, neuroblastoma cells (mouse), 207
- muscarinic receptor stimulation, receptor reserve, astrocytoma cells, 200
- pathways, calcium mobilization, hepatocytes (guinea pig), 315
- phosphorylation of tyrosine hydroxylase, pheochromocytoma PC12 cells, 476

Cyclic GMP, multiple muscarinic receptors, neuroblastoma cells (mouse), 207

Cyclic nucleotides, bradykinin and nitroprusside, effects on fibroblasts, 274

Cytochrome P-450

- ferrochelate-inhibitory activity, *N*-alkylprotoporphyrin formation, 352
- isozyme 3a, nasal and kidney microsomes, alcohol induction (rabbit), 370
- liver
 - mechanism-based inactivators, dichloromethyl compounds (rat), 19
 - oxidation of quinidine, 287
- lung, monooxygenase system (rabbit), 296
- pulmonary microsomal, *N*-alkylaminobenzotriazoles, suicide inhibitors (rat, rabbit), 25
- reductase, binding sites, NADPH (rat), 178

Cytoskeleton, guanine nucleotide-binding regulatory proteins, fractionation of the β subunit, 463

D

Daunomycin, comparative binding affinities, double-stranded oligomeric DNA, 279

Daunorubicin, anthracycline-binding polypeptides, photoaffinity labeling, heart, 388

3-Deazaadenosine, homocysteine and *S*-3-deazaadenosylhomocysteine, metabolic effects, 154

S-3-Deazaadenosylhomocysteine, homocysteine and, disposition, exposure to 3-deazaadenosine, 154

10-Deazaaminopterins, polyglutamates and, inhibitory action, thymidylate synthase, 149

Debrisoquine hydroxylase, quinidine oxidation, liver cytochrome P-450, 287

19-nor-11-Deoxycorticosterone, binding affinity, mineralocorticoid receptor, 585

Dibutyl cyclic AMP, neural hybrid cells, N_1 -coupled receptors (mouse), 526
 Dichloroacetamides, cytochrome P-450, mechanism-based inactivators, liver (rat), 19
 Dichlorobenzamil, cation flux pathways (chick), 164
 Dichloromethyl compounds, mechanism-based inactivators, liver cytochromes P-450 (rat), 19
 3,5-Diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine, ferrochelate-inhibitory activity, *N*-alkylprotoporphyrin formation, 352
 Dihydrofolate reductase, regulation, human breast cancer cells and mutant hamster cells, minigene transfection, 69
 Dihydropyridine, sensitivity, calcium channels, distribution in CNS, 505
 Dihydropyridine enantiomers, studies on calcium channels, intact cardiac cells (rat), 571
 Dihydropyridines, ferrochelate-inhibitory activity, *N*-alkylprotoporphyrin formation, 352
 Dihydrotrabenazine, binding, striatal synaptic vesicles (bovine), 252
 γ -Diketone, 2,5-hexanedione-treated protein, pyrrole adduct autooxidation, 452
 6,7-Dimethyl-4-(4'-amino-3'-iodobenzyl)isoquinoline, isoquinoline binding site, intestine, 379
 Dimethyl sulfoxide, actions, neuromuscular transmission (mouse), 631
 Dipeptidylaminopeptidase, enkephalin-degrading, active site, selective inhibition (porcine), 338
 Diphenoxiquone, metabolic activation of phenol, myeloperoxidase and horseradish peroxidase, 674
 Dipyrindamole, inhibition, nucleotide transport system (guinea pig), 659
 DNA
 damage in L5178YS cells, exposure to benzene metabolites, 42
 lesions, piritrexim-induced, 651
 Dopamine, D-2 receptors, thermodynamics, agonist and antagonist binding (rat), 226
 Dopaminergic 2-aminotetralins, dopamine D-2 receptor affinities, molecular structures, conformational preferences, 258

E

5,6,11,14-Eicosatetraynoic acid, bradykinin and nitroprusside, effects on fibroblasts, 274
 Electron paramagnetic resonance, mitochondrial membranes, effect of sodium valproate (rat), 270
 Endothelium-derived relaxing factor, sodium-calcium exchange and calcium entry blockers, endothelial-mediated responses, aorta (rat), 53
 Enkephalins, dipeptidylaminopeptidase, degradation, active site and selective inhibition (porcine), 338
 Erythrocytes, nucleotide transport system, dipyrindamole inhibition (guinea pig), 659
 Erythropoiesis, vitamin D₃ derivatives, 639
 Estrogen, dihydrofolate reductase minigene transfection, human breast cancer cells and mutant hamster cells, 69
 Ethanol, acute and chronic effects, phosphatidylinositol 4,5-bisphosphate breakdown, brain (mouse), 13
N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, effects on putative muscarinic receptor subtypes, brain (rat), 96
 Ethyl β -carboline-3-carboxylate, benzodiazepine receptor ligands, chloride ionophore, γ -aminobutyric acid (rat), 218
 10-Ethyl-10-deazaaminopterin, inhibitory action, thymidylate synthase, 149
N-Ethylmaleimide, mammalian cardiac membranes, spontaneous coupling to N_s, β -adrenergic receptor (rat, cat, guinea pig), 1

F

Ferrochelate, implications for active site, *N*-alkylprotoporphyrin formation, 352
 Fibroblasts, effects, bradykinin and nitroprusside, 274

FLA 797, remoxipride hydrochloride and, solid state conformations, antidopaminergic effects, 345
 Flavin, monooxygenase, lung (rabbit), 680
 FMLP, receptor, calcium influx, neutrophils, 437
N-Formyl-L-methionyl-L-phenylalanine: see FMLP
 Forskolin, effect of cholera toxin, adenylate cyclase activation, calmodulin, 469
 Friend erythroleukemia cells, inhibited differentiation, vitamin D₃ derivatives, 639

G

GABAergic agents, kinetics of *t*-butylbicyclophosphorothionate binding (rat), 321
 Gallamine, binding, muscarinic M1 and M2 receptors (rat), 58
 Glioma, turnover of β_1 - and β_2 -adrenergic receptors, down-regulation or irreversible blockade (rat), 104
 Glioma cells, radioligand selectivity, multiple subtypes, quantitative method, 329
 Glucocorticoids
 cyclic AMP and
 induction of mRNA, tyrosine hydroxylase, 497
 induction of tyrosine hydroxylase, pheochromocytoma cells, 486
 Glutathione
 depletion, modulated cytotoxicity, cisplatin and melphalan, 643
 horseradish peroxidase and, styrene cooxidation, 666
 metabolic activation of phenol, myeloperoxidase and horseradish peroxidase, 674
 reduced, acetaminophen and NADPH, reactions with *N*-acetyl-*p*-benzoquinone imine, 33
 Glycine, strychnine-binding sites, Eccles' anions, modulatory effect of cations, 598
 Glycogen synthase, hexose-independent activation, pyruvate dehydrogenase, insulin (mouse), 624
 Guanine nucleotides, derivatives, ability to bind and activate bovine transducin, 603
 Guanine nucleotides, acetylcholine mustard binding, cardiac cholinergic muscarinic receptors, 411
 Guanine-*O*⁶-alkyl-transferase, loss of activity, selection of nitrogen mustard resistance, tumor cell line (rat), 77

H

Haloperidol, lithium and, proenkephalin-A gene regulation, striatum (rat), 186
 Heart
 anthracycline-binding polypeptides, photoaffinity labeling, 388
 muscarinic receptor classes (rat), 305
 Heart cells, inhibited cation flux pathways, dichlorobenzamil (chick), 164
 Hepatic steatosis, valproate, inhibited ketogenesis, liver lobule (rat), 520
 Hepatocytes, cyclic AMP pathways, calcium mobilization (guinea pig), 315
 Hepatotoxicity, carbon tetrachloride, liver plasmalemmal vesicles, membrane permeability, 444
 2,5-Hexanedione, treated protein, pyrrole adduct autooxidation, 452
 Hexose, glycogen synthase and pyruvate dehydrogenase, activation by insulin (mouse), 624
 Hippocampus, brainstem and, muscarinic receptors, effect of solubilization (rabbit), 193
 Homocysteine, S-3-deazaadenosylhomocysteine and, disposition, exposure to 3-deazaadenosine, 154
 Horseradish peroxidase
 glutathione and, styrene cooxidation, 666
 myeloperoxidase and, metabolic activation of phenol, 674
 Hydrogen, sodium exchange and, inhibition, neutrophils by amiloride analogues, 112

- 4-Hydroxybiphenyl, liver morphine, UDP-glucuronosyltransferase, isolation and purification (rat), 558
 21-Hydroxypregna-4,11-diene-3,20-dione, binding affinity, mineralocorticoid receptor, 585
 8-Hydroxyquinoline, antimalarial activity, aromatic chelators, cation uptake, 364
 5-Hydroxytryptamine, *see* Serotonin

I

- Imipramine, binding site, neuronal serotonin uptake and, single-site model (rat), 121
 Immunocytochemistry, cytochrome P-450 isozyme 3a, nasal and kidney microsomes (rabbit), 370
 Indomethacin, bradykinin and nitroprusside, effects on fibroblasts, 274
 Inositol phosphates
 cyclic AMP pathways, calcium mobilization (guinea pig), 315
 leukotriene B₄-induced formation, peritoneal polymorphonuclear leukocytes (rat), 235
 Insulin, activation, glycogen synthase and pyruvate dehydrogenase (mouse), 624
 Intestine, isoquinoline binding site, 6,7-dimethyl-4-(4'-amino-3'-iodobenzyl)isoquinoline, 379
 Iodochohydroxyquin, antimalarial activity, aromatic chelators, cation uptake, 364
 Iodopindolol
 mammalian cardiac membranes, spontaneous coupling to N_S, β -adrenergic receptor (rat, cat, guinea pig), 1
 radioligand selectivity, multiple subtypes, quantitative method, 329
 Iron chelators, α -ketohydroxypyridine (mice), 670
 Isoproterenol, turnover of β_1 - and β_2 -adrenergic receptors, down-regulation or irreversible blockade (rat), 104
 Isozymes, lung cytochrome P-450, monooxygenase system (rabbit), 296

K

- Ketogenesis, inhibition, hepatic steatosis, valproate (rat), 520
 α -Ketohydroxypyridine, iron chelators (mice), 670
 Kidney, microsomes, cytochrome P-450 isozyme 3a, alcohol induction (rabbit), 370

L

- L1210 cells, glutathione-modulated cytotoxicity, cisplatin and melphalan, 643
 Leukemia cells, basophilic, 5-lipoxygenase and leukotriene A₄ synthetase activities (rat), 510
 Leukocytes, peritoneal polymorphonuclear, inositol phosphate formation, leukotriene B₄-induced (rat), 235
 Leukotriene A₄, basophilic leukemia cells (rat), 510
 Leukotriene B₄, induced inositol phosphate formation, peritoneal polymorphonuclear leukocytes (rat), 235
 Lipophilicity, dopamine D-2 receptors, agonist and antagonist binding (rat), 226
 5-Lipoxygenase, basophilic leukemia cells (rat), 510
 Lithium, haloperidol and, proenkephalin-A gene regulation, striatum (rat), 186
 Liver
 angiotensin II receptors, high yield photoaffinity labeling (rat), 544
 cytochrome P-450
 mechanism-based inactivators, dichloromethyl compounds (rat), 19
 oxidation of quinidine, 287
 ferrochelatase-inhibitory activity, *N*-alkylprotoporphyrin formation, 352
 hepatic steatosis, valproate, inhibited ketogenesis (rat), 520
 morphine, UDP-glucuronosyltransferase, isolation and purification (rat), 558
 plasmalemmal vesicles, membrane permeability, 444

- Lung
 flavin-containing monooxygenase (rabbit), 680
 Lung cells, cytochrome P-450, monooxygenase system (rabbit), 296
 LY195115, inhibitor of cyclic nucleotide phosphodiesterase, sarcoplasmic reticulum, 609
 L5178YS cells, DNA damage, exposure to benzene metabolites, 42

M

- Macrophages
 lung cytochrome P-450, monooxygenase system (rabbit), 296
 peripheral alveolar, superoxide anion generation, bleomycin (pig), 48
 Mammalian cells, nocodazole-resistant mutants, cross-resistance, microtubule inhibitors, 142
 MCF-7 cells, dihydrofolate reductase minigene transfection, human breast cancer cells and mutant hamster cells, 69
 Melphalan, cisplatin and, glutathione-modulated cytotoxicity, ovarian carcinoma and L1210 cells, 643
 Metalloproteinase, enkephalin-degrading dipeptidylaminopeptidase, active site, selective inhibition (porcine), 338
 Methotrexate, dihydrofolate reductase minigene, human breast cancer cells and mutant hamster cells, 69
N- α -Methylbenzylaminobenzotriazole, pulmonary microsomal P-450, *N*-alkylaminobenzotriazoles, suicide inhibitors (rat, rabbit), 25
 Methyl β -carboline-3-carboxylate, benzodiazepine receptor ligands, chloride ionophore, γ -aminobutyric acid (rat), 218
 10-Methyl-10-deazaaminopterin, inhibitory action, thymidylate synthase, 149
N-Methylscopolamine, muscarinic receptor classes, brain (rat), 305
 Microsomes, nasal and kidney, cytochrome P-450 isozyme 3a, alcohol induction (rabbit), 370
 Microtubule, inhibitors, nocodazole-resistant mutants, cross-resistance and CHO cells, 142
 Mitochondria, membranes, effects of sodium valproate (rat), 270
 Monooxygenase, flavin-containing, lung (rabbit), 680
 Monooxygenase system, cytochrome P-450, lung (rabbit), 296
 Morphine, liver, UDP-glucuronosyltransferase, isolation and purification (rat), 558
 Muscle, smooth, relaxants, isoquinoline binding site, 379
 Mycobactin P, antimalarial activity, aromatic chelators, cation uptake, 364
 Myeloperoxidase, horseradish peroxidase and, metabolic activation of phenol, 674
 Myocytes
 activation by insulin, glycogen synthase and pyruvate dehydrogenase (mouse), 624
 batrachotoxin A benzoate, binding, cardiac sodium channels (rat), 617

N

- NADH fluorescence, hepatic steatosis, valproate (rat), 520
 NADPH
 cytochrome P-450 reductase, binding sites (rat), 178
 reduced glutathione and acetaminophen, reactions with *N*-acetyl-*p*-benzoquinone, 33
 NAPQI, reactions with *N*-acetyl-*p*-benzoquinone, reduced glutathione, acetaminophen and NADPH, 33
 Neocarcinostatin, auroomycin cleavage and bleomycin, Simian virus 40 DNA and chromatin, 358
 Neural hybrid cells, N_i-coupled receptors (mouse), 526
 Neuroblastoma cells, multiple muscarinic receptors (mouse), 207
 Neuroleptics
 dopamine D-2 receptors, agonist and antagonist binding (rat), 226
 remoxipride hydrochloride and FLA 797, solid state conformations, antidopaminergic effects, 345
 Neuromuscular junction, actions of dimethyl sulfoxide (mouse), 631
 Neuropeptides, lithium and haloperidol, proenkephalin-A gene regulation, striatum (rat), 186

- Neurotransmitter, benzodiazepine receptor ligands, chloride ionophore, γ -aminobutyric acid (rat), 218
- Neutrophils
 plasma membrane, calcium influx, fMet-Leu-Phe receptor, 437
 sodium-hydrogen exchange, inhibition, amiloride analogues, 112
- Nicotine, binding sites, brain, 427
- Nifedipine oxidase, quinidine oxidation, liver cytochrome P-450, 287
- Nitrobenzylthioinosine, nucleotide transport system, dipyridamole inhibition (guinea pig), 659
- Nitrogen mustard, resistance selection, loss of guanine- O^6 -alkyl transferase activity (rat), 77
- Nitroprusside, bradykinin and, effects on fibroblasts, 274
- Nitrosourea, selection of nitrogen mustard resistance, loss of activity, guanine- O^6 -alkyl-transferase (rat), 77
- Nocodazole, cross-resistance of mutants, microtubule inhibitors, benzimidazole carbamate derivatives, 142
- Nuclear magnetic resonance, dopaminergic 2-aminotetralins, dopamine D-2 receptor affinities, molecular structures, 258
- Nucleotide phosphodiesterase, cyclic, LY195115 inhibitor, sarcoplasmic reticulum, 609
- Nucleotides, transport system, nitrobenzylthioinosine-sensitive, dipyridamole inhibition (guinea pig), 659
- O**
- Occupancy theory, photoaffinity labeling, A₁ adenosine receptors, spare receptors, 403
- Opioids
 agonist binding
 sodium regulation, 81
 sodium regulation (guinea pig), 90
 lithium and haloperidol, proenkephalin-A gene regulation, striatum (rat), 186
- Ouabain, inhibited cation flux pathways, dichlorobenzamil, heart cells (chick), 164
- P**
- Papaverine, isoquinoline binding site, 379
- PC12 cells, nicotinic acetylcholine receptor function, carbamylcholine-induced loss, 6
- Peptide mapping, phosphorylation of tyrosine hydroxylase, pheochromocytoma PC12 cells, 476
- pH, sodium-hydrogen exchange, inhibition, amiloride analogues, 112
- Phencyclidine, spin-labeled anesthetic, acetylcholine receptor, 243
- Phenobarbital, liver plasmalemmal vesicles, membrane permeability, 444
- Phenol, metabolic activation, human myeloperoxidase and horseradish peroxidase, 674
- Phenylarsine oxide, inhibited photolabeling changes, β -adrenergic receptors, 459
- Phenylquinoline, benzodiazepine receptor ligands, chloride ionophore, γ -aminobutyric acid (rat), 218
- Pheochromocytoma cells
 cyclic AMP and glucocorticoids, induction of mRNA, tyrosine hydroxylase, 497
 induction of tyrosine hydroxylase, cyclic AMP and glucocorticoids, 486
- Pheochromocytoma PC12 cells, phosphorylation of tyrosine hydroxylase, 476
- Phorbol esters, muscarinic receptor stimulation, receptor reserve, astrocytoma cells, 200
- Phosphatidylinositol 4,5-bisphosphate, receptor-mediated breakdown, acute and chronic effects of ethanol, brain (mouse), 13
- Phosphodiesterase, inhibitor, LY195115, sarcoplasmic reticulum, 609
- Phosphoinositide hydrolysis
 muscarinic receptor stimulation, receptor reserve, astrocytoma cells, 200
- stimulation, adenylate cyclase inhibition, muscarinic receptor reserve (chick), 566
- Phosphorylation, tyrosine hydroxylase, pheochromocytoma PC12 cells, 476
- Photoaffinity labeling
 A₁ adenosine receptors, persistent activation, spare receptors, 403
 anthracycline-binding polypeptides, heart, 388
 high yield, angiotensin II receptors (rat), 544
- Pirenzepine, muscarinic receptor classes, brain (rat), 305
- Pirenzepine
 acute and chronic effects of ethanol, phosphatidylinositol 4,5-bisphosphate breakdown (mouse), 13
 putative muscarinic receptor subtypes, *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline treatment (rat), 96
 quinuclidinylbenzilate and, gallamine binding, muscarinic M1 and M2 receptors (rat), 58
- Piritrexim, induced DNA lesions, 651
- Plasma membrane
 neutrophils, calcium influx, fMet-Leu-Phe receptor, 437
 permeability, liver plasmalemmal vesicles, 444
- Plasmodium falciparum*, cation uptake, aromatic chelators, antimalarial activity, 364
- Podophyllotoxin, nocodazole-resistant mutants, cross-resistance, microtubule inhibitors, 142
- Polyglutamates, 10-deazaaminopterin and, inhibitory action, thymidylate synthase, 149
- Polymorphism, quinidine oxidation, liver cytochrome P-450, 287
- Polypeptides, anthracycline-binding, photoaffinity labeling, heart, 388
- Potassium channels, cyclic AMP pathways, calcium mobilization (guinea pig), 315
- Proenkephalin-A, gene regulation, lithium and haloperidol, striatum (rat), 186
- Prohormone, atriopressin, proteolytic processing (rabbit), 552
- Propyl β -carboline-3-carboxylate, benzodiazepine receptor ligands, chloride ionophore, γ -aminobutyric acid (rat), 218
- Prostaglandins, bradykinin and nitroprusside, effects on fibroblasts, 274
- Protein
 basophilic leukemia cells, 5-lipoxygenase and leukotriene A₄ activities (rat), 510
 guanine nucleotide-binding, fractionation of the β subunit, cytoskeleton, 463
 2,5-hexanedione-treated, pyrrole adduct autooxidation, 452
- Protein kinases, phosphorylation of tyrosine hydroxylase, pheochromocytoma PC12 cells, 476
- Protein, transmembrane movement, mitochondrial membranes, sodium valproate (rat), 270
- Protooncogenes, 1- β -D-arabinofuranosylcytosine, effects on expression, U937 cells, 398
- Pulmonary monooxygenase system, microsomal cytochrome P-450, isozyme-selective suicide inhibitors (rat, rabbit), 25
- Pyrimidine, *de Novo* pathway, uracil nucleotide synthesis, MCF-7 human cancer cells, 136
- Pyrrole, adduct autooxidation, 2,5-hexanedione-treated protein, 452
- Pyruvate dehydrogenase, activation by insulin (mouse), 624
- Q**
- Quinidine, oxidation, liver cytochrome P-450, 287
- Quinuclidinyl benzilate
 multiple muscarinic receptors, neuroblastoma cells (mouse), 207
 pirenzepine and, gallamine binding, muscarinic M1 and M2 receptors (rat), 58
- R**
- Radioligand, nonpeptide, peripheral receptors, cholecystokinin (rat), 212
- Radioligand, selectivity, quantitative method, multiple receptor subtypes, 329

- Rate theory, photoaffinity labeling, A₁ adenosine receptors, spare receptors, 403
- Receptor reserve, muscarinic, adenylate cyclase inhibition, phosphoinositide hydrolysis stimulation (chick), 566
- Receptors
- A₁ adenosine, photoaffinity labeling, 403
 - acetylcholine
 - nicotinic, carbamylcholine-induced loss of function, 6
 - spin-labeled local anesthetic, 243
 - adenohypophyseal, vasopressin antagonists (rat), 171
 - β -adrenergic
 - photolabeling changes, phenylarsine oxide inhibition, 459
 - spontaneous coupling to N_s, mammalian cardiac membranes (rat, cat, guinea pig), 1
 - γ -aminobutyric acid, desensitization, chloride ion channel, 419
 - β_1 - and β_2 -adrenergic, turnover, down-regulation or irreversible blockade (rat), 104
 - angiotensin II, high yield photoaffinity labeling (rat), 544
 - atrial natriuretic factor, bovine adrenal zona glomerulosa, 537
 - cholinergic, acute and chronic effects of ethanol, brain (mouse), 13
 - dopamine, remoxipride hydrochloride and FLA 797, solid state conformations, 345
 - dopamine D-2, thermodynamics, agonist and antagonist binding (rat), 226
 - glycine, allosteric interaction, strychnine-binding sites (rat), 590
 - mineralocorticoid, binding affinity, aldosterone derivatives, 585
 - multiple subtypes, radioligand selectivity, quantitative method, 329
 - muscarinic
 - acetylcholine mustard binding, 411
 - classes, brain (rat), 305
 - effect of solubilization, hippocampus and brainstem (rabbit), 193
 - M1 and M2, gallamine binding (rat), 58
 - neuroblastoma cells (mouse), 207
 - receptor reserve, astrocytoma cells, 200
 - treatment with *N*-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, brain (rat), 96
 - N_i-coupled, neural hybrid cells (mouse), 526
 - neurotoxin, binding, cardiac sodium channels (rat), 617
 - nicotinic, brain, 427
 - opioid
 - agonist binding, sodium regulation (guinea pig), 90
 - agonist binding, sodium regulation, 81
 - peripheral, cholecystokinin, nonpeptide radioligand (rat), 212
- Red tides, brain synaptosomes, brevetoxins, sodium channel activation (rat), 129
- Remoxipride hydrochloride, solid state conformations, antidopaminergic effects, 345
- Reserpine, dihydrotetrabenazine binding, striatal synaptic vesicle (bovine), 252
- Rhodotorulic acid, antimalarial activity, aromatic chelators, cation uptake, 364
- RNA
- messenger
 - lithium and haloperidol, proenkephalin-A gene regulation (rat), 186
 - tyrosine hydroxylase induction, cyclic AMP and glucocorticoids, 497
- S**
- Sarcoplasmic reticulum, inhibited cyclic nucleotide phosphodiesterase, LY195115, 609
- Serotonin, uptake and imipramine-binding site, single-site model (rat), 121
- SIBFA procedure, comparative binding affinities, daunomycin derivatives, double-stranded oligomeric DNA, 279
- Simian virus 40, chromatin and, bleomycin, neocarzinostatin and auromycin cleavage, 358
- Sodium
- calcium exchange and, calcium entry blockers, endothelial-mediated responses in aorta (rat), 53
 - hydrogen exchange and, inhibition. neutrophils by amiloride analogues, 112
 - neuronal serotonin uptake, imipramine-binding site, single-site model (rat), 121
 - regulation
 - agonist binding, opioid receptors, 81
 - agonist binding, opioid receptors (guinea pig), 90
- Sodium-calcium exchange, inhibited cation flux pathways, dichlorobenzamil (chick), 164
- Sodium channels, voltage-sensitive, activation by brevetoxins, brain synaptosomes (rat), 129
- Sodium valproate, mitochondrial membranes, transmembrane protein movement studies (rat), 270
- Spinal cord, glycine receptor, strychnine-binding sites, allosteric interaction (rat), 590
- Steroids, aldosterone derivatives, binding affinity, mineralocorticoid receptor, 585
- Striatum
- effect of cholera toxin, adenylate cyclase activation, calmodulin, 469
 - muscarinic receptor classes (rat), 305
 - proenkephalin-A gene regulation, influence of lithium and haloperidol (rat), 186
- Strychnine
- glycine-binding sites
 - allosteric interaction (rat), 590
 - Eccles' anions, modulatory effect of cations, 598
- Styrene, cooxidation, horseradish peroxidase and glutathione, 666
- Substrate analogues, homogenous uridine kinase, Ehrlich ascites tumor, 159
- Suicide inhibitors, isozyme-selective, pulmonary microsomal cytochrome P-450, *N*-alkylaminobenzotriazoles (rat, rabbit), 25
- Superoxide anions, generation, bleomycin, peripheral alveolar macrophages (pig), 48
- Synaptic vesicle, striatal, dihydrotetrabenazine binding (bovine), 252
- Synaptoneuroosomes, desensitization of GABA receptor, chloride ion channel, 419
- Synaptosomes, brain, brevetoxins, sodium channel activation (rat), 129
- T**
- Tamoxifen, dihydrofolate reductase minigene transfection, human breast cancer cells and mutant hamster cells, 69
- Thermodynamics, dopamine D-2 receptors, agonist and antagonist binding (rat), 226
- Thiabendazole, nocodazole-resistant mutants, cross-resistance, microtubule inhibitors, 142
- Thymidylate synthase, 10-deazaaminopterin and their polyglutamates, inhibitory action, 149
- Toxins, brain synaptosomes, brevetoxins, sodium channel activation (rat), 129
- Transducin, bovine, guanine nucleotide derivatives, binding and activation, 603
- Tumor cells, Ehrlich ascites, homogenous uridine kinase, bisubstrate analogs, 159
- Tyrosine hydroxylase
- induction by cyclic AMP and glucocorticoids, pheochromocytoma cell line, 486
 - phosphorylation, pheochromocytoma PC12 cells, 476
- U**
- U937 cells, 1- β -D-arabinofuranosylcytosine, effects on protooncogene expression, 398
- UDP-glucuronosyltransferase, liver morphine, isolation and purification (rat), 558

Uracil, nucleotide synthesis, MCF-7 human cancer cells, *de novo* pyrimidine pathway, 136
 Uridine kinase, homogenous, from Ehrlich ascites tumor, bisubstrate analogs, 159

V

Valproate, hepatic steatosis, inhibited ketogenesis, liver lobe (rat), 520
 Vasopressin, antagonists, novel vasopressin receptor, adenohypophysis (rat), 171

Vesicles, striatal synaptic, dihydrotetrabenazine binding (bovine), 252
 Vitamin D₃, derivatives, inhibited differentiation, Friend erythroleukemia cells, 639

X

X-ray
 crystallographic analysis, aldosterone derivatives, mineralocorticoid receptor, 585
 solid state conformations, remoxipride hydrochloride, FLA 797, 345

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$30.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. William A. Catterall, Editor, *Molecular Pharmacology*, Department of Pharmacology, SJ-30, University of Washington, Seattle, Washington 98195, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$30 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made.

Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary. All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text,

including title and complete pagination. Examples: 1. Goren, J. H., L. G. Baue, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7) Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers *after* such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used (\times , \circ , \bullet , \square , \blacksquare , \triangle , \blacktriangle , \odot). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.